Peptide-hydrolase-inhibitors/tenofovir-disoproxil-fumarate

Chronic kidney disease and osteoporosis: case report

    Reactions Weekly volume 1838, page436(2021)Cite this article

    This is a preview of subscription content, access via your institution.

    Access options

    Buy single article

    Instant access to the full article PDF.

    US$ 49.95

    Tax calculation will be finalised during checkout.

    Reference

    1. Maibam A, et al. Looking beyond tenofovir renal toxicity as the cause of bone disease in HIV. Journal of the American Society of Nephrology 30 (Suppl.): 862 (plus poster) abstr. SA-PO383, 2019. Available from: URL: https://www.asn-online.org/education/kidneyweek/archives/ [abstract]

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Peptide-hydrolase-inhibitors/tenofovir-disoproxil-fumarate. Reactions Weekly 1838, 436 (2021). https://doi.org/10.1007/s40278-021-89753-9

    Download citation